Solid phase immunoassay for C trachomatis

The development of chlamydial antigen detection kits has led to the wider availability of diagnostic services for this organism. Currently, two technologies are readily available; immunofluorescence microscopy and enzyme linked immunosorbant assay (EIA). Neither technology is perfect, with problems of sensitivity and of specificity. Advances continue, and it is important that new kits are properly evaluated against chlamydial cell culture in both high and low risk populations.

Solid phase immunoassay (IA) tests are simple to use, requiring little technical expertise. They are likely to become popular as "office" tests. We recently evaluated the performance of a novel IA utilising coloured latex particles (Clearview Chlamydia, Unipath, Bedford, UK) for cervical specimens against conventional cell culture.

Specimens from the cervix of 148 women attending the Genitourinary Medicine Departments of the Middlesex Hospital and University College Hospital were examined. Two cotton tipped swabs were taken from the cervix, one was expressed into 2SP transport medium for chlamydial culture, and the other was used for immuno-assay. The order of taking the swabs was determined from a random number table.

Chlamydial culture utilised cycloheximide treated McCoy cells, grown on glass coverslips in plastic vials. All specimens were inoculated in duplicate, and one of each pair subjected to a single blind passage. The presence of Chlamydia trachomatis was confirmed using a specific immunofluorescent monoclonal antibody stain (Microtrak, Syva Cor., Palo Alto, Calif.).

Swabs for immunoassay were processed according to the manufacturers' instructions. In brief, the swab plus extraction reagent were held at 80°C for 10 minutes. The swab was then discarded. After cooling, 5 drops of the extract were added to the sample window of the test unit. The appearance of a blue/black line in the result window within 15 minutes was taken to indicate the presence of chlamydial antigen (positive and negative controls were included in each batch). Discrepant results were further evaluated by application of the Syva Microtrak Direct Immunofluorescence (DIF) test to the remaining immunoassay extract, and examining for stained elementary bodies.

C. trachomatis was isolated from 34 of 148 women (23%). There were seven discrepant results (see table), all were culture positive, immunoassay negative. One of the seven (immunoassay swab taken first) was positive with the Microtrak DIF test. The other six were all randomised to have the immunoassay swab taken second, and were negative on DIF. This could reflect low levels of antigen on the swab. The specificity, sensitivity, predictive value of a positive result (PVP), predictive value of a negative result (PVN), and agreement were 79-4%, 100%, 100%, 94-2% and 95-27%, respectively, for the Clearview immunoassay compared with cell culture.

In our hands, the Clearview Chlamydia immunoassay test compares favourably with other immunoassays evaluated against our cell culture system. We found that sensitivity was low compared to our results for the Abbott Chlamydiiazyme, and Pharmacia EIA tests (92-3%, 90-5%, respectively), and indeed lower than the 93-5% sensitivity reported by Arumainayagam et al in a recently reported comparison of Clearview against cell culture. A similar degree of sensitivity was found with the Ortho Chlamydia EIA test (80%). Specificity and PVP were excellent, as reported by Arumainayagam and co-workers. This indicates that the test will be reliable for both high and low risk populations. However, the lower sensitivity compared to other enzyme immunoassays may restrict its use in the latter group. The test was simple to use, requiring a dry swab without the need for a special transport medium. The test took an average of 40 minutes to perform, and the endpoint was clear.

The test is not as yet available for use on specimens from the male urethra, or other sites.

G L RIDGWAY
G MUMTAZ
E ALLASON-JONES
J S BINGHAM*
Departments of Microbiology and G-U Medicine*,
Chlamydia and Middlesex Hospitals,
London WC1E 6AU


Susceptibility of Haemophilus ducreyi to spermicidal compounds, in vitro

The active ingredients of spermicidal preparations are known to have antimicrobial activity against most of the causative organisms of sexually transmitted diseases, in vitro and in vivo. Clinical studies have also confirmed that spermicides can provide effective prophylaxis against the infections in vivo. Haemophilus ducreyi is endemic in many African and other third-world countries where it is the commonest...
Solid phase immunoassay for C trachomatis.

G L Ridgway, G Mumtaz, E Allason-Jones and J S Bingham

doi: 10.1136/sti.67.3.268

Updated information and services can be found at:
http://sti.bmj.com/content/67/3/268.1.citation

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/